Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), that is at least as fast as [salbutamol], combined with a long duration of action (12 hours) – for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product and in several formulations in combination with both inhaled corticosteroids and long-acting muscarinic antagonists. It is grouped under the following drug class(es): Beta-2 agonists and Bronchodilators. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Foradil, Oxis and Eformoterol. Its PubChem CID is 3410.
Formoterol
| CAS No | 73573-87-2 |
|---|---|
| Molecular Formula | C19H24N2O4 |
| Molecular Weight | 344.41 g/mol |
| Synonyms | N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers.
The listed CAS number is 73573-87-2.
The listed molecular formula is C19H24N2O4.
The listed molecular weight is 344.41 g/mol.
N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide.
The source lists Foradil, Oxis and Eformoterol.